In vitro and in vivo studies on the metabolism of tirofiban.

  title={In vitro and in vivo studies on the metabolism of tirofiban.},
  author={Stanley Vickers and Anthony D. Theoharides and Byron H. Arison and Suresh K. Balani and Donghui Cui and Carolyn A Duncan and Joan D. Ellis and L M Gorham and Sarit Polsky and Thomayant Prueksaritanont and Harri G Ramjit and Donald E Slaughter and Kamlesh P Vyas},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  volume={27 11},
Tirofiban hydrochloride [L-tyrosine-N-(butylsulfonyl)-O-[4-(4-piperidinebutyl)] monohydrochloride, is a potent and specific fibrinogen receptor antagonist. Radiolabeled tirofiban was synthesized with either (3)H-label incorporated into the phenyl ring of the tyrosinyl residue or (14)C-label in the butane sulfonyl moiety. Neither human liver microsomes nor liver slices metabolized [(14)C]tirofiban. However, male rat liver microsomes converted a limited amount of the substrate to a more polar… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 14 extracted citations

Updates in antiplatelet agents used in cardiovascular diseases.

Journal of cardiovascular pharmacology and therapeutics • 2013
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 23 references

Role of human cytochrome P 4502 A 6 in Coxidation of nicotine

RS Obach, HV Vunakis
Drug Metab Dispos • 1996

Binding of the fibrinogen receptor antagonist tirofiban to purified GPIIb/IIIa and to platelets (Abstract 256)

B Bednar, SL Gaul, +6 authors RJ Gould
FASEB J • 1995
View 1 Excerpt

Demonstration of potent inhibition of platelet aggregation with an orally active GPIIb/IIIa receptor antagonist

RJ Anders, JC Alexander, +4 authors DJ Fitzgerald
J Am Coll Cardiol • 1995
View 1 Excerpt

Pharmaco-dynamics and -kinetics of BIBU 52, a platelet glycoprotein (GP) IIb/IIIa antagonist, and its orally active prodrug BIBU 104 in man

TH Muller, H Weisenberger, +5 authors J Krause
Thromb Haemost • 1995
View 1 Excerpt

Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb / IIIa inhibitors

DE Williams, MK Shigenaga, N Castagnoli
Am Heart J • 1995

A dosing study in high-risk PTCA of MK-383, a platelet GP IIb/IIIa antagonist

D Kereiakes, N Kleiman, +8 authors FL Sax
Circulation • 1994
View 1 Excerpt

A randomized double-blind controlled trial with the non-peptide platelet GP IIb/IIIa antagonist Ro 44–9883 in unstable angina

S Kouz, ML Knudtson, +6 authors H Rapold
Circulation • 1994
View 1 Excerpt

Profound sustained and reversible platelet inhibition following administration of a glycoprotein IIb/IIIa inhibitor with and without heparin in patients with unstable angina

RA Harrington, SP Schulman, +7 authors MM Kitt
Circulation • 1994
View 1 Excerpt

Similar Papers

Loading similar papers…